China's Innovent Biologics May Look Into M&As, CFO Says

The video discusses a biopharmaceutical company's journey from its establishment in 2011 to becoming a major player in the industry. It highlights the company's achievements, including the development of a fully integrated platform and successful commercialization of biological products. The discussion covers market competition, particularly in China, and the company's strategies for global expansion through collaborations with international giants like Eli Lilly. Financial strategies, including a recent $610 million share placement, are also discussed, along with future plans for product development and market penetration.

What year was the company established?

• 2010

• 2013

• 2011

• 2012

How many products does the company currently have in development?

• 20

• 30

• 15

• 23

Which international giant is the company collaborating with?

• Sanofi

• Novartis

• Eli Lilly

• Pfizer

What is the main focus of the company's collaborations?

• Research and Development

• Marketing

• Sales

• Manufacturing

What is the company's strategy to become a global biopharma player?

• Increase local sales

• Reduce product prices

• Focus on domestic market

• Collaborate with international companies

How much money did the company raise for R&D and clinical trials?

• $700 million

• $800 million

• $610 million

• $500 million

What are the company's plans for future development?

• Stop collaborations

• Reduce R&D efforts

• Expand operations globally

• Focus only on China